First-Ever Combination Immunotherapy Receives Approval by the FDA

Thursday, October 1, 2015

The US Food and Drug Administration approved the immunotherapy combination nivolumab (Opdivo®) plus ipilimumab (Yervoy®) for use in patients with metastatic melanoma. Memorial Sloan Kettering’s medical oncologist and cancer immunologist Jedd Wolchok, created and tested the combination and led the clinical trials that resulted in FDA approval.  Patients who have received this new drug combination are also available for interview. For more information and to set up interviews, email Nicole McNamara at